{
  "docId": "019de071-dd7f-730a-8977-e46a36e30dcf",
  "docSlug": "abc22aebd2d55a5159142df321cabcee",
  "documentTitle": "Bionomics | IPO Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7391304,
  "pageNumber": 38,
  "pageCount": 38,
  "prevPage": 37,
  "nextPage": null,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Details the financial milestones (A$118M) and strategic partnership for CAR-T therapy development.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-dd7f-730a-8977-e46a36e30dcf/38",
  "deckHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf",
  "deckJsonHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf.json",
  "deckAnchorHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "image",
      "text": "carina biotech",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc0b6c2b-3a27-43ae-8146-7430779c3b27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.45,
        "y": 0.15
      },
      "kind": "list",
      "text": "Exclusive Agreement to license Bionomics' BNC101 oncology drug candidate to Carina Biotech for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body's immune system to fight cancer. Bionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development. In September 2021, Carina announced that it plans to initiate a clinical trial of BNC101 CAR-T therapy for the treatment of advanced colorectal (bowel) cancer in late 2022. Bionomics retains BNC101 for other types of therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33eaaf97-be1a-4910-9a11-9e63223d9fcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.07,
        "y": 0.04
      },
      "kind": "title",
      "text": "Legacy Oncology Asset Monetization to Drive Value: BNC101",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe74d1a8-094b-43f7-9ba3-f7800b3b03ae",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5c0f72f4-93d8-42d3-81a3-8e70589dd97f",
      "evidence": "The slide contains a list of bullet points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}